Adenosine A 2A receptor (A 2A R) blockade enhances innate and adaptive immune responses. However, mouse genetic studies have shown that A 2A R deletion does not inhibit the growth of all tumor types. In the current study, we showed that growth rates for ectopic melanoma and bladder tumors are increased in Adora2a À/À mice within 2 weeks of tumor inoculation. A 2A R deletion in the host reduced numbers of CD8 þ T cells and effector-memory differentiation of all T cells. To examine intrinsic functions in T cells, we generated mice harboring a T-cell-specific deletion of A 2A R. In this host strain, tumor-bearing mice displayed increased growth of ectopic melanomas, decreased numbers of tumor-associated T cells, reduced effector-memory differentiation, and reduced antiapoptotic IL7Ra (CD127) expression on antigen-experienced cells. Intratumoral pharmacologic blockade similarly reduced CD8 þ T-cell density within tumors in wild-type hosts. We found that A 2A R-proficient CD8 þ T cells specific for melanoma cells displayed a relative survival advantage in tumors. Thus, abrogating A 2A R signaling appeared to reduce IL7R expression, survival, and differentiation of T cells in the tumor microenvironment. One implication of these results is that the antitumor effects of A 2A R blockade that can be mediated by activation of cytotoxic T cells may be overcome in some tumor microenvironments as a result of impaired T-cell maintenance and effector-memory differentiation. Thus, our findings imply that the efficacious application of A 2A R inhibitors for cancer immunotherapy may require careful dose optimization to prevent activation-induced T-cell death in tumors.
Introduction
Solid tumors produce high concentrations of adenosine in response to hypoxia, cell necrosis, and the rapid metabolism of extracellular adenine nucleotides by ecto-nucleotidases expressed on tumor cells, tumor cell exosomes, and T regulatory cells (1) (2) (3) (4) . Adenosine engages four adenosine receptor subtypes: A 1 , A 2A , A 2B , and A 3 . The adenosine A2A receptor (A 2A R) is the predominant subtype found on T cells, and is induced upon cell activation (4, 5) .
A 2A R signaling inhibits innate and adaptive immune responses (5, 6) . Global deletion of A 2A Rs facilitates activation of CD8 þ T cells and enhances rejection of certain tumors that were genetically engineered to be highly sensitive to cytotoxic T-cell killing due to overexpression on tumor cells of MHC-I molecules (7) . A 2A R deletion also enhances lymphoma killing and the effectiveness of an antilymphoma tumor vaccine (8) . Hence, adenosine has been viewed as an inhibitor of T-cell-mediated tumor surveillance (9, 10) , and blockade of lymphocyte A 2A Rs has been advocated to facilitate tumor immunotherapy. Curiously, global deletion of A 2A Rs did not affect the growth of B16F10 melanomas or MB49 bladder carcinomas that were not modified by genetic engineering (7, 11) , despite the fact that these tumors produce immune cell activation (12) . This might occur because adenosine levels are high in solid tumors, and A 2A R signaling can inhibit activation-induced death of T cells and thus facilitate their survival (13) . It is also possible that some of the effects of global A 2A R deletion on tumor growth are due to disinhibition of tumor macrophages, dendritic cells (DC), or natural killer (NK) cells.
In contrast with the failure of global A 2A R deletion to inhibit B16F10 growth, reduced adenosine production due to deletion of CD73, an ecto-enzyme that converts AMP to adenosine, was found to consistently enhance antitumor adaptive immune responses (6, (14) (15) (16) (17) . This could be in part due to the involvement of A 2B Rs in tumor suppression (11) or to differential effects on immune cell function caused by moderately reducing A 2A R stimulation by deleting CD73 as opposed to eliminating A 2A R signaling by deleting receptors.
In the current study, we evaluated the effects on B16F10 melanoma growth and tumor-associated T-cell survival of: (i) global A 2A R deletion, (ii) LckCre-mediated T-cell selective deletion of floxed A 2A Rs, and (iii) adoptive cotransfer of T cells to tumor-bearing mice with and without A 2A Rs. The results indicate that T-cell-specific A 2A R deletion does activate T cells, but can also lead to reduced numbers of tumorassociated T cells and an increase over time in the growth rate of large solid tumors. Hence, some degree of A 2A R signaling is needed for maintenance and effector differentiation of tumor-associated T cells. Opposing effects of A 2A R deletion to enhance T-cell activation but to reduce effector cell numbers in solid tumors provide an explanation for why global deletion of the A 2A R causes inconsistent effects on tumor growth.
Materials and Methods

Cell lines, animals, and reagents
Animal experiments were approved by the ACUC of the La Jolla Institute (La Jolla, CA). B16F10 cells stably expressing luciferase were obtained from Caliper Life Sciences. MB49 bladder carcinoma cells were from Dr. Timothy Ratliff of Purdue University (West Lafayette, IN). MB49 Bladder carcinomas were characterized as indicated by Luo and colleagues (18) and further tested at the time of experimentation for adherence, freeze thaw viability, growth properties, and mouse MHCI expression, without further authentication. Ovalbuminexpressing B16F10 cells produced as described previously (19) were a gift of Dr. Stephen Schoenberger of the La Jolla Institute. Ovalbumin and luciferase-expressing B16F10 cells were obtained from Dr. Andreas Limmer of the University of Bonn (Bonn, Germany). Both ovalbumin-expressing melanoma cell lines were received within 6 months of experimentation and evaluated at the time of experimentation by morphology, adherence, freeze thaw viability, growth properties, mouse MHCI expression before and after IFNg treatment, cell surface expression of MHCI/Ova peptide complexes, and antigenspecific recognition of TRP2 or OVA peptides by respective transgenic T cells. B16F10 cells were cultured in R5F (RPMI-1640 medium containing 10% heat-inactivated FBS, 2 mmol/L L-glutamine, 1 mmol/L sodium pyruvate, 50 U/mL penicillin, and 50 mg/mL streptomycin). Tumor cells were injected into mice after reaching 60% to 80% confluence. A 2A R KO mice produced by Chen and colleagues (20) on a mixed genetic background were backcrossed onto C57BL/6. Six-week-old C57BL/6J, EGFPþ, and OT-I Rag À/À mice were purchased from Jackson Laboratories, crossed with Adora2a À/À mice, and used for experiments after being acclimated for 2 to 6 weeks. LckCre þ mice (21) were obtained from Taconic (B6.CgTg(Lck-cre)1Cwi N9) and used to create
mice. Tail DNA from all mice was genotyped (Transnetyx, Inc.) to detect the presence of Cre recombinase and to quantify by qPCR lckCre-mediated excision of floxed Adora2a DNA. Global versus lck-mediated Cre expression was found to increase the amount of excision by >20-fold in tail DNA. Hence, qPCR was used to exclude from experiments occasional mice with nonlymphoid deletion. As further evidence of lymphoid-selective deletion, we have shown previously by qPCR that thymocyte expression of A2AR mRNA in lckCre/Adora2a f/f mice is only deleted after thymocytes activate lck (22) . Yellow or aqua fluorescent reactive dyes were from Invitrogen. SIINFEKLloaded H2K b tetramers with human b-2 microglobilin were provided by the NIH tetramer core facility. Fluorescent antibodies used in this study, their sources, and dilutions are listed in Supplementary Table S1 .
Flow cytometry
Single-cell suspensions from indicated tissues were prepared by sequential pressing through 100 and 40 mm cell strainers. Dead cells were removed from tumor samples by Ficoll gradient centrifugation at 2,000 rpm (900 g) for 20 minutes at room temperature. After RBC lysis (Biolegend) of spleen samples, remaining cells were washed and resuspended in R10F, and counted in a Z2-Coulter particle counter (BeckmanCoulter). Cells (3-5 Â 10 6 ) were preincubated for 10 minutes in 100 mL FACS buffer with antibody to block Fc receptors. Each sample tube received 100 mL fluorescently labeled antibody cocktail and was incubated for 30 minutes at 4 C in the dark. Cells were analyzed using an LSRII equipped with 4 lasers or a LSR Fortessa equipped with 5 lasers and FACS Diva software (BD Biosciences). Live/dead fixable yellow, aqua, or blue (Invitrogen) was used to exclude dead cells before analysis. Flow-cytometric data were analyzed using FlowJo software (9.5.3 version, TreeStar Software Inc.).
Establishment and in vivo imaging of solid tumors
B16F10 or MB49 cells (10 5 ) were injected into the right flanks of mice. B16F10 melanoma cells expressing luciferase were injected into Adora2a f/f -LckCre À/þ and used for in vivo imaging. Tumor volumes were measured using digital calipers and calculated as height Â width 2 /2. Luciferase activity was determined using an IVIS 200 Bioluminescence imager (Caliper Life Sciences) after intravenous injection of 1 mg D-Luciferin (Caliper Life Sciences) in 100 mL PBS to validate that tumor size differences were not due to infiltration of host cells. To measure tumor metastasis, 3 Â 10 5 B16F10 melanoma cells expressing luciferase were injected intravenously into mouse tail veins and luciferase activity was measured in the lungs 1 and 2 weeks later. After measuring luciferase activity, lungs were removed, photographed, and weighted to validate that luciferase activity correlated with tumor mass.
Adoptive transfer and cotransfer of T cells B16F10 cells (10 5 ) expressing ovalbumin (B16F10-OVA) were injected into mouse flanks and allowed to expand for 16 days. Mixtures of 3 Â 10 6 OT-1 Rag À/À and 7 Â 10 6 OT-1 Rag
Adora2a
À/À cells were injected intraperitoneally. 
Results
Global deletion of Adora2a increases solid tumor growth and impairs CD8 þ T-cell effector differentiation and accumulation in tumors In prior studies, global deletion of A 2A Rs failed to slow the growth rate of B16F10 melanomas transplanted into syngeneic mice (7, 11 ). In the current study, we performed similar experiments in mice inoculated with B16F10 melanoma or MB49 bladder carcinomas and confirmed that A 2A R deletion failed to decrease the rate of growth of either tumor; in fact, the growth rates of both tumors were significantly increased at days 14 to 18 after inoculation as the tumors became large (Fig. 1A) . By preparing single-cell suspensions of tumors grown for 18 days after tumor inoculation, we next determined whether increased B16F10 growth was associated with reduced accumulation and/or impaired function of particular immune cell types within the tumor. Adora2a experiments; E). Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001; ÃÃÃÃ , P < 0.0001, by two-way ANOVA and Bonferroni post hoc analyses for A and Student t test for B-E. Fig. 2A, top) . CD4 þ T-cell effector differentiation (as measured by CD44 and KLRG1) was also significantly inhibited in the absence of Adora2a (Fig. 2A, bottom) . After global A 2A R deletion,
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Geom. mean CD80 expression on tumor-associated APCs increased, whereas CD86 expression and NK markers were unchanged ( Fig. 2B and C) . We also evaluated phenotypic markers in tumor-associated myeloid APCs such as MHCII, PD-1, and PD-L1, which regulate T-cell activation and CD39, which mediates tolerogenic activity of DCs by converting immunostimulatory ATP to ADP and AMP. A 2A R deficiency did not cause significant changes among any of these markers except for a reduction in cell surface PD-L1 expression (Supplementary Fig. S1 ). PD-L1, although inhibitory for T-cell activation, can be upregulated by inflammatory signals. It is possible that a reduction in the production of inflammatory cytokines due to reduced T-cell accumulation and activation contributes to reduced PD-L1 expression in A 2A R-deficient mice. Overall, these results suggest that decreased CD8 to home to inflamed sites. We did not observe any reduction in CXCR3 expression after A 2A R deletion (Fig. 3B) . Furthermore, local inhibition by intratumoral injection of the A 2A R antagonist FSPTP, but not by selective A 2B R blocker ATL-801, also significantly reduced the frequency of tumor-associated CD8 þ T cells (Fig. 3C) , suggesting that as in melanomas, A 2A R signaling facilitates the accumulation CD8 þ T cells within bladder tumors as well.
It is notable that A 2A R blockade consistently increased the frequencies of tumor-associated NK cells (Figs. 1B  and 3A and C) . This observation agrees with findings by Beavis and colleagues (2) Fig. S2 ) of solid tumors, suggesting that Adora2a f/f -LckCre þ/À mice have normal T-cell development compared with littermate controls. However, T-cell selective deletion of A 2A Rs markedly accelerated the growth rate of tumors after they reached a volume >500 mm 3 ( Fig. 4A and B ; see Supplementary Fig. S3 for results of individual experiments). These findings suggest that paradoxically, some degree of A 2A R signaling in T cells is required to mount an optimal antitumor immune response in large solid tumors. A 2A R signaling increases cAMP production (24) . It has been suggested that a temporary increase in cAMP levels may be required for T-cell activation (25) . However, A 2A R deletion failed to affect the expression of CD69 in tumor-associated T cells (Supplementary Fig. S4 ). We reasoned that the absence of A 2A R signaling in the tumor microenvironment might cause T cells to polarize toward a regulatory phenotype. Figure 4C shows that T-cell A 2A R deletion does not enhance regulatory T-cell differentiation in the tumor or tumor draining lymph nodes. Therefore, we measured CD25 expression in antigen-experienced T-cell populations. The deletion of the A 2A R from lymphocytes increased CD25 expression in tumor-associated/antigen-experienced CD44 hi Foxp3 À CD4 þ
T cells and did not affect CD8 þ T cells or lymph node
CD44hiFoxp3-CD4 þ T cells (Fig. 4D ). These data suggest that deletion of A 2A R signaling does not hamper T-cell activation in tumors.
We next considered the possibility that A 2A R signaling sustains normal numbers of tumor-associated T cells. We found previously that A 2A R signaling, by activating PKA, reduces the activity of the PI3K/Akt pathway (22) . This suppresses TCR-mediated downregulation of antiapoptotic CD127, which is upregulated in long-lived effector-memory cells and required for their maintenance. LckCre-mediated deletion of A 2A Rs significantly reduced CD127 expression in antigen-experienced T cells in the tumor (Fig. 5) Tumor sizes were measured by caliper (n > 9 from two independent experiments; ÃÃÃ , P < 0.0001, by two-way ANOVA and Bonferroni post hoc analysis). B, luciferase luminescence was measured after injecting 1 mg/mouse of luciferin into tumor-bearing mice (n > 4 from one of two independent experiments). Data were analyzed by the Student t test. Single-cell suspensions from tumors and lymph nodes (LN) were isolated from Adora2a f/f -LckCre þ/À or Cre À/À littermate controls harvested 3 weeks after tumor inoculation. C, intracellular staining for Foxp3. D, surface staining for CD25 was performed; n ¼ 4 from one of two independent experiments with similar results. Data were analyzed using two-way ANOVA and Bonferroni post hoc tests.
significantly reduced the frequencies of tumor-associated T cells ( Fig. 6A and B) but not NK cells (Fig. 6C ). T-cellselective A 2A R-deletion also significantly reduced the frequency of CD44 þ effector-memory T cells in tumors, but not lymph nodes ( Fig. 6D and E) . Figure 6F shows a reduction in A 2A R À/À T-cell density in tumors. Hence, although A 2A R activation during TCR stimulation inhibits T-cell activation, the data suggest a role for adenosine in maintaining effector T cells within the tumor microenvironment. These opposing effects of A 2A R deletion to enhance T-cell activation but to reduce effector cell numbers provide an explanation for why global deletion of the A 2A R causes small or inconsistent effects on tumor growth.
A 2A R signaling prolongs the maintenance of T cells in tumor-bearing hosts Global A 2A R deletion significantly reduces the development and peripheral maintenance of na€ ve T cells (22) . Although Lck-mediated Adora2a f/f deletion did not affect thymic progression of T cells, it did cause a decrease in the number of naive T cells in the periphery. This decrease in the na€ ve T-cell population may contribute to reducing numbers of T cells in tumors after global or LckCre-mediated deletion of Adora2a f/f . Also, reduced na€ ve T-cell numbers in mice lacking T-cell A 2A Rs could be a consequence of high tumor burden rather than to an intrinsic effect of A 2A R signaling. To evaluate in vivo competition and phenotypic differentiation of antigen-specific T cells lacking or expressing A 2A Rs in the same tumor microenvironment, we performed adoptive cotransfer experiments. When cotransferred into the same host-bearing B16F10-OVA tumors, the proportion of Adora2a À/À OT-1 T cells was markedly decreased in the tumor relative to Adora2a þ/þ OT-1 T cells (Fig. 7A) . A 2A R deletion also reduced cell surface expression of PD-1 (Fig. 7B) , whereas CD25 expression was increased (Fig.  7C) , a phenotype similar to what was observed after global deletion of the A 2A R (Fig. 2A) . Figure 7D shows that A 2A R deletion caused a significant decrease in CD127 expression in both spleen and tumor-associated OT-I T cells.
To directly test the effects of Adora2a deletion on T-cell survival and effector-memory differentiation, we adoptively transferred Adora2a þ/þ and Adora2a À/À OT-I T cells 2 weeks after establishment of B16F10-OVA tumors in congenic hosts. One week after adoptive transfer, we prepared single-cell suspensions from tumor tissue by ficoll gradient and measured cell surface staining of Annexin V as an apoptosis marker, CD44 as marker for effector-memory differentiation, and CD127 as mediator of T-cell survival. Tumor-associated but not splenic Adora2a À/À OT-I T cells expressed significantly more Annexin V than Adora2a þ/þ OT-I T cells and this was associated with decreased expression of CD44 and CD127 within tumors ( Supplementary Fig. S5 ). Transfer of either Adora2a þ/þ or Adora2a À/À OT-I cells induced a transient decrease in tumor growth, suggesting that Adora2a À/À cells are initially functional, but immunostimulatory effects of Adora2a deletion appear to be counteracted by reduced survival/effector-memory differentiation ( Supplementary  Fig. S5 ). Overall, these data show that in the tumor environment, A 2A R-deficient T cells have a survival disadvantage as compared with A 2A R-proficeint T cells.
Discussion
Adenosine accumulates to high levels in solid tumors (1-4). A 2A Rs on antigen-presenting cells and T cells, and A 2B receptors on antigen-presenting immune cells are primarily responsible for immunosuppression by adenosine (26, 27) . Global deletion or intratumoral blockade of A 2B Rs delays the growth of lung and bladder carcinoma and breast cancers, consistent with the immunosuppressive roles of these receptors (11) . Curiously, global A 2A R deletion failed to slow the growth of bladder carcinomas and B16BL6 melanomas (7, 11) , but was found to enhance the rejection of CL8-1 cells that were genetically engineered to be highly immunogenic by transfection with H-2K b (7) . These findings, and the results of the current study suggest that A 2A R blockade, as a strategy to treat cancer, is more complex than previously thought (9, 10) . Although T cells are acutely activated by A 2A R deletion, long-term T-cell-mediated solid tumor rejection is compromised, likely as a result of impaired maintenance of T cells and reduced effector-memory differentiation in the tumor. It is important to point out, however, that the T cells go through an expansion phase after activation but many fail to survive either due to excess activation of inhibitory signals, or due to the absence of costimulation by certain cytokines or homing signals in the tumor (9) . Interestingly, the absence of T-cell intrinsic inhibitory A 2A R signaling reduces numbers of tumor-associated T cells after 2 to 3 weeks of solid tumor expansion. Our recent findings indicate that A 2A R signaling can prevent TCR-induced downregulation of antiapoptotic CD127 (22) . A 2A R deficiency significantly reduced the development and peripheral maintenance of na€ ve T cells. This decrease in the na€ ve T-cell population may contribute to reduced numbers of T cells in tumors after Lck-mediated deletion of Adora2a f/f . However, the irreversible A 2A R antagonist, FSPTP, injected directly into solid tumors, also reduced tumorassociated T-cell numbers in wild-type recipients. Also, the ratio of antigen-specific A 2A R-deficient/A 2A R-proficient T cells decreased within the same tumor after adoptive cotransfer, suggesting a T-cell survival defect due do either deletion or irreversible blockade of A 2A R signaling in the tumor environment.
We show that CD127 expression by effector-memory cells in tumors is significantly reduced in T cells lacking A 2A Rs, whereas CD25 expression is largely intact or even increased. This supports the notion that although A 2A R signaling acutely inhibits initial T-cell activation, A 2A R-dependent control of CD127 expression may be necessary for the maintenance of T cells after they differentiate into long-lived effectormemory cells. Consistent with this idea, we noted a significant impairment in the ex vivo survival of A 2A R À/À T cells in response to IL7 (22) . The pattern of tumor T-cell responses caused by deletion of the A 2A R is very similar to the effect of IL2 in tumor immunotherapy: although IL2 increases the activation and early expansion of T cells, it causes increased activation-induced death (28) . Therefore, it is possible that CD127 deficiency and increased IL2 signaling due to increased CD25 expression impair T-cell survival in the tumor microenvironment. A 2A R signaling may sustain tumor-associated T cells by inhibiting the PI3K/Akt pathway. As with A 2A R agonists, PI3K is also inhibited by rapamycin, which has been shown to increase numbers of long-lived effector-memory T cells in virally infected mice (29) . Expansion of tumor-associated effector-memory T cells might account for the observations that despite their immunosuppressive properties, adenosine (this study) and rapamycin (30) have antiapoptotic effects on T cells in some tumors.
The A 2A R is upregulated in multiple immune cell types upon activation (5, 31, 32) . Blockade or deletion of A 2A Rs in NK cells (2) or myeloid cells (23) significantly inhibits tumor growth and metastasis and is associated with transactivation of cytotoxic lymphocytes. Consistent with these findings, the current study suggests that to avoid apoptosis of tumorassociated T cells, myeloid or NK cell targeted therapies should be considered as preferable targets for A 2A R deletion/blockade as a strategy for tumor immunotherapy. Alternatively, to optimize the beneficial effects of T-cell activation by A 2A R blockade for solid tumor killing, it may be necessary to find complementary strategies to enhance T-cell survival and effector-memory differentiation to counteract activation-induced cell death. These concepts apply not only to the potential use of adenosine receptor blockade or deletion to treat cancer, but also more broadly to the general use of T-cell activators.
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